Quantum BioPharma

02/10/2026

What happens when illegal market activity collides with medical research?

In this clip, I talk with the team at Quantum BioPharma about alleged stock spoofing and market activity that the company says interfered with their ability to fund and advance a promising MS drug.

It is a rare look at how financial misconduct can directly impact scientific progress and patients waiting for answers.

02/06/2026

02/06/2026

02/06/2026

Hope in the Lab: A Drug to Protect Myelin | Hope & Health with Mathew Embry Episode #020 featuring Quantum BioPharma $QNTM

▶️ Watch the full episode: https://youtu.be/bJ6a52DaQMo

What does it really take to move a promising MS therapy from the lab to patients?

In Episode 20 of Hope & Health with Mathew Embry, Dr. Andrzej Chruscinski, Vice President, Clinical and Scientific Affairs, and Anthony Durkacz, Founder & Executive Co-Chairman of the Board, discuss Quantum BioPharma and Lucid MS — a first-in-class compound designed to protect the myelin sheath by targeting mechanisms linked to demyelination, rather than suppressing the immune system.

The episode also examines emerging science around citrullination and its role in myelin damage and disease progression, alongside the real-world challenges of advancing early-stage research — including funding obstacles and alleged stock spoofing and market interference that disrupted progress.

Hosted by Mathew Embry, filmmaker and advocate, the conversation offers a candid look at what happens when scientific promise, financial markets, and patient hope collide.

Hope & Health with Mathew Embry is a weekly talk show exploring health, wellness, and resilience through science, strategies, and personal stories. Filmmaker...

02/02/2026

At Quantum BioPharma, we’re advancing science with the goal of improving outcomes for people living with multiple sclerosis.

Learn more about Lucid-MS:
https://www.quantumbiopharma.com/lucid-ms $QNTM

01/13/2026

Alleged stock spoofing takes center stage as Quantum BioPharma Co-Founder Anthony Durkacz speaks with host Tracy Hughes

David vs 13 Goliaths.’ Anthony Durkacz explains why Quantum BioPharma ($QNTM) launched a $700M class action over alleged stock spoofing by major banks, saying everyday investors were harmed, market integrity was undermined, and that while fighting manipulation, the company continues advancing Lucid-MS toward Phase 2 to help MS patients

youtu.be/fk_R0cpg7aY?si…

$QNTM

From the outset of his conversation with InvestorNews.com host Tracy Hughes, Anthony Durkacz pulled no punches: the fight his company has launched against al...

01/05/2026

Learn more about Lucid-MS by visiting our website https://www.quantumbiopharma.com/lucid-ms

$QNTM

12/31/2025

Happy New Year from all of us at Quantum BioPharma.

Thank you to our shareholders, partners, and supporters for being part of our journey.

Wishing everyone a healthy and successful year ahead.

$QNTM

12/24/2025

Happy Holidays from Quantum BioPharma.
We extend our best wishes to our shareholders, stakeholders, and partners, and wish everyone a healthy season ahead.

12/23/2025

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

Studies Will Support Investigational New Drug Application (IND) with the US FDA, Including Design of Phase 2 Trial

https://www.globenewswire.com/news-release/2025/12/23/3209828/0/en/Quantum-Biopharma-Announces-Completion-of-Dosing-in-180-Day-Repeated-Dose-Oral-Toxicity-and-Toxicokinetic-Studies-for-Lucid-21-302-Lucid-MS.html

$QNTM

12/19/2025

World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

https://globenewswire.com/news-release/2025/12/19/3208756/0/en/World-Renowned-Law-Firm-Grant-Eisenhofer-Files-Class-Action-Lawsuit-Against-Canadian-Banks-CIBC-and-RBC-Alleging-Illegal-Stock-Market-Manipulation-of-Quantum-BioPharma-Shares.html

$QNTM

12/10/2025

Most people think MS is just the immune system attacking myelin — but one of the earliest changes happens insidethe myelin itself.
A healthy myelin sheath relies on Myelin Basic Protein (MBP) to stay compact and stable.

But in MS, MBP can undergo citrullination — a chemical modification that changes the protein’s charge and weakens its structure.
When MBP becomes citrullinated, the myelin layers loosen, electrical conduction slows, and the axon becomes far more vulnerable to demyelination.

➡️ MBP citrullination → myelin instability → demyelination → neurological decline.
This upstream biology is becoming an important area of research in understanding how MS progresses over time.

Quantum BioPharma is focused on advancing science in this space and exploring how targeted small molecules may support healthier myelin structure and function.

Understanding citrullination is key. Understanding demyelination is essential. Advancing research matters.
$QNTM